Steve Byrne

Steve Byrne Recent News

Why This LyondellBasell Analyst Dropped Their Bearish Stance
Shares of LyondellBasell Industries NV (NYSE: LYB) have underperformed peers, despite a similar reduction in forecasts and offering a dividend that seems to be sustainable, according to BofA Securities.
Agricultural Chemical Companies Had A Good Start To 2020, And BofA Says It's Over
While agricultural chemicals companies reported significant volume growth in the first quarter, U.S.-centric suppliers have likely peaked, according to BofA Securities.
BofA Downgrades LyondellBasell, Dow, Says Polyethylene Producers Face Margin Pressure
The rebound in polyethylene is likely to be more challenging and companies like LyondellBasell Industries NV (NYSE: LYB) and The Dow Chemical Company (NYSE: DOW) could generate only modest earnings gains through 2021, accordi
BofA Turns Bearish On Livent After Bullish Conference Call
Bank Of America Upgrades CF Industries On Strong Q2, Improving 2020 Outlook
New DuPont 'Built For Success,' BofA Says In Bullish Initiation
BofA Downgrades Mosaic, Cites Phosphate Pricing Pressure
Mosaic Earns Double Upgrade On Sustainable Recovery In Phosphate
A Look Ahead At DowDuPont's Catalysts Over The Next Year; Analyst Initiates At Buy
Potash Corp Hit By Bank Of America Downgrade And Shares Are Falling
Bank Of America Upgrades Sarepta Therapeutics On 'Increased Conviction' Of Drug Approval
UPDATE: Bank Of America Reiterates On BioCryst Pharmaceuticals Following EU Physicians Survey
Bank Of America Q3 Small & Mid-Cap Biotech Preview
Bank Of America Sees Significant Manufacturing Capacity Expansions Underway For Pacira Pharmaceuticals
UPDATE: Bank Of America Downgrades Seattle Genetics, Inc. On Frontline Expectations
UPDATE: Bank Of America Reiterates On Vital Therapies On Improved Outlook
UPDATE: Bank Of America Downgrades Theravance As Pricing Headwinds Continue
UPDATE: Bank Of America Reiterates On Pacira Pharmaceuticals On Positive Survey Results
UPDATE: Bank Of America Reiterates On BioCryst Pharmaceuticals On Modestly Positive HAE Data
UPDATE: Bank of America Upgrades Seattle Genetics On Trial Risks
UPDATE: Bank of America Reiterates on Karyopharm Therapeutics on Significant Catalysts in 2014
UPDATE: Bank of America Reinstates Coverage on Incyte on Two Oncology Platforms
UPDATE: Bank of America Downgrades Vivus as Partnering Prospects Weaken